Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alector ( (ALEC) ) has shared an announcement.
On October 21, 2025, Alector announced a significant workforce reduction of approximately 49% to align with strategic priorities following the results of the Phase 3 INFRONT-3 clinical trial for latozinemab (AL001) in frontotemporal dementia, which did not meet its primary endpoint. The company is discontinuing the open-label extension and continuation study for latozinemab, impacting around 75 employees with restructuring charges estimated at $7.7 million. Additionally, Sara Kenkare-Mitra, President and Head of Research and Development, resigned effective December 22, 2025, to pursue other opportunities, with a separation agreement in place. Despite the trial’s outcome, Alector remains committed to advancing its pipeline, including ongoing collaborations and preclinical programs, supported by its proprietary ABC platform.
The most recent analyst rating on (ALEC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Alector stock, see the ALEC Stock Forecast page.
Spark’s Take on ALEC Stock
According to Spark, TipRanks’ AI Analyst, ALEC is a Neutral.
Alector’s overall stock score reflects significant financial challenges and a difficult valuation environment, partially offset by positive technical momentum and a strong cash position. The company’s strategic focus on advancing clinical trials offers potential upside, but regulatory and diagnostic hurdles remain.
To see Spark’s full report on ALEC stock, click here.
More about Alector
Alector, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing therapies to counteract neurodegenerative diseases. The company leverages genetics, immunology, and neuroscience to advance a portfolio of programs aimed at removing toxic proteins, replacing missing proteins, and restoring immune and nerve cell function. Alector is also developing a proprietary blood-brain barrier platform, Alector Brain Carrier (ABC), to enhance therapeutic delivery and efficacy.
Average Trading Volume: 1,289,863
Technical Sentiment Signal: Hold
Current Market Cap: $335M
Learn more about ALEC stock on TipRanks’ Stock Analysis page.